Autologous cell suspension grafting using ReNovaCell in non-segmental vitiligo patients: a randomized controlled study - ReNovaCell in non-segmental vitiligo

Academisch Medisch Centrum0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月23日

试验速览

暂无简介。

•Patients with, non-segmental vitiligo receiving 6 months of standard of care, consisting of topical corticosteroids or immune modulators and NB-UVB phototherapy
•Age >=18
•Patient is willing and able to give written informed consent
•At least two comparable (in location and diameter) depigmented lesions of at least 10 cm2 or one large lesion of at least 30 cm2 on the extremities, face or trunk - excluding fingers, elbows, feet and knees.

•- Patients with signs of activity (spreading of lesions and/or koebnerisation) during standard of care treatment or showing depigmentation in the test punch grafting
•- Skin type I
•- Recurrent HSV skin infections
•- Hypertrophic scars
•- Cardiac insufficiency
•- Patients with a history of hypersensitivity to (UVB or UVA) light and/or allergy to local anaesthesia.
•- Patients who are pregnant or breast-feeding
•- Patients not competent to understand what the procedures involves
•- Patients with a personal history of melanoma or non-melanoma skin cancer
•- Patients with atypical nevi.
•- Known allergy to clarithromycin

发起方